JP7732974B2 - 腸疾患に対する免疫原性組成物およびその調製のための方法 - Google Patents

腸疾患に対する免疫原性組成物およびその調製のための方法

Info

Publication number
JP7732974B2
JP7732974B2 JP2022514468A JP2022514468A JP7732974B2 JP 7732974 B2 JP7732974 B2 JP 7732974B2 JP 2022514468 A JP2022514468 A JP 2022514468A JP 2022514468 A JP2022514468 A JP 2022514468A JP 7732974 B2 JP7732974 B2 JP 7732974B2
Authority
JP
Japan
Prior art keywords
antigen
polysaccharide
salmonella enterica
enterica serovar
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022514468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546763A5 (https=
JP2022546763A (ja
Inventor
デーレー，ラジーブ・ムホーラサカント
ピサール，サンバージー・シャンカル
アナムラジュ，ダタトレーヤ・サルマ
アバラスカール，ニクヒル・ダタトレー
ハンデカリ，ヨーゲシ・ツカラム
タクリカール，アニル・ピラジラオ
ゴエル，スニール・クマール
カマット，チャンドラシェーカル・ドワルカナト
チャバン，ビシャール・バーラト
Original Assignee
セラム インスティチュート オブ インディア プライベイト リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラム インスティチュート オブ インディア プライベイト リミテッド filed Critical セラム インスティチュート オブ インディア プライベイト リミテッド
Publication of JP2022546763A publication Critical patent/JP2022546763A/ja
Publication of JP2022546763A5 publication Critical patent/JP2022546763A5/ja
Priority to JP2024160658A priority Critical patent/JP2024178271A/ja
Application granted granted Critical
Publication of JP7732974B2 publication Critical patent/JP7732974B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022514468A 2019-09-03 2020-09-02 腸疾患に対する免疫原性組成物およびその調製のための方法 Active JP7732974B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024160658A JP2024178271A (ja) 2019-09-03 2024-09-18 腸疾患に対する免疫原性組成物およびその調製のための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921035435 2019-09-03
IN201921035435 2019-09-03
PCT/IN2020/050763 WO2021044436A2 (en) 2019-09-03 2020-09-02 Immunogenic compositions against enteric diseases and methods for its preparation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024160658A Division JP2024178271A (ja) 2019-09-03 2024-09-18 腸疾患に対する免疫原性組成物およびその調製のための方法

Publications (3)

Publication Number Publication Date
JP2022546763A JP2022546763A (ja) 2022-11-08
JP2022546763A5 JP2022546763A5 (https=) 2023-08-01
JP7732974B2 true JP7732974B2 (ja) 2025-09-02

Family

ID=72659843

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514468A Active JP7732974B2 (ja) 2019-09-03 2020-09-02 腸疾患に対する免疫原性組成物およびその調製のための方法
JP2024160658A Pending JP2024178271A (ja) 2019-09-03 2024-09-18 腸疾患に対する免疫原性組成物およびその調製のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024160658A Pending JP2024178271A (ja) 2019-09-03 2024-09-18 腸疾患に対する免疫原性組成物およびその調製のための方法

Country Status (23)

Country Link
US (2) US20230149524A1 (https=)
EP (2) EP4249061A3 (https=)
JP (2) JP7732974B2 (https=)
KR (2) KR20240155975A (https=)
CN (1) CN114728053A (https=)
AR (1) AR119884A1 (https=)
AU (1) AU2020343943A1 (https=)
BR (1) BR112022003892A2 (https=)
CA (1) CA3149972A1 (https=)
CO (1) CO2022003789A2 (https=)
CR (1) CR20220132A (https=)
EC (1) ECSP22031077A (https=)
GB (2) GB2603362B (https=)
GE (2) GEP20257808B (https=)
IL (1) IL291006B2 (https=)
JO (1) JOP20200214A1 (https=)
MA (1) MA56283A1 (https=)
MX (1) MX2022002693A (https=)
PE (1) PE20221442A1 (https=)
PH (1) PH12022550525A1 (https=)
PY (1) PY2051122A (https=)
WO (1) WO2021044436A2 (https=)
ZA (1) ZA202203368B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121569027A (zh) * 2023-07-21 2026-02-24 葛兰素史克生物有限公司 免疫原性组合物
WO2025217253A1 (en) * 2024-04-12 2025-10-16 Neogen Corporation Neutralizing compositions and related methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026799A1 (en) 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
JP2010514818A (ja) 2007-01-04 2010-05-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CN102935226A (zh) 2012-11-16 2013-02-20 罗益（无锡）生物制药有限公司 伤寒甲型副伤寒结合疫苗及其制备方法
US20130129776A1 (en) 2011-11-07 2013-05-23 University Of Maryland, Baltimore Broad Spectrum Vaccine Against Typhoidal and Non-typhoidal Salmonella Disease
US20130209503A1 (en) 2012-01-20 2013-08-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
WO2015029056A1 (en) 2013-08-24 2015-03-05 Bharat Biotech International Limited A bacterial vaccine and methods for manufacture thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
FR2938265B1 (fr) 2008-11-12 2011-07-15 Univ Claude Bernard Lyon Procede pour le pilotage d'un traitement de depolymerisation par ultrasons d'un biopolymere hydrosoluble
CA2836153C (en) * 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
MX354103B (es) 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
CN104383532A (zh) * 2014-12-02 2015-03-04 云南沃森生物技术股份有限公司 一种用乙肝表面抗原为载体蛋白的细菌多糖蛋白结合物疫苗及其制备方法
CN104587461A (zh) * 2015-01-05 2015-05-06 云南沃森生物技术股份有限公司 伤寒、甲型乙型副伤寒多糖蛋白结合型多价联合疫苗
WO2017006349A1 (en) * 2015-07-04 2017-01-12 Bharat Biotech International Limited Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
US20190134177A1 (en) * 2016-04-25 2019-05-09 National Institute Of Immunology Conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate
MY191163A (en) 2016-08-26 2022-06-03 The Centers For Disease Control And Prevention Cdc Multivalent vaccine composition
US11739356B2 (en) * 2017-05-05 2023-08-29 Serum Institute Of India Private Limited Method for removal of impurities from bacterial capsular polysaccharide based preparations
CN111032078A (zh) 2017-07-18 2020-04-17 血清研究所印度私人有限公司 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法
EA202190778A1 (ru) 2018-10-12 2021-08-05 Серум Инститьют Оф Индия Прайват Лтд Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения
MX2021005500A (es) * 2018-11-10 2021-09-08 Bharat Biotech Int Ltd Composiciones inmunogenicas de glicoconjugados multivalentes.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998026799A1 (en) 1996-12-18 1998-06-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugate vaccine for salmonella paratyphi a
JP2010514818A (ja) 2007-01-04 2010-05-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US20130129776A1 (en) 2011-11-07 2013-05-23 University Of Maryland, Baltimore Broad Spectrum Vaccine Against Typhoidal and Non-typhoidal Salmonella Disease
US20130209503A1 (en) 2012-01-20 2013-08-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
CN102935226A (zh) 2012-11-16 2013-02-20 罗益（无锡）生物制药有限公司 伤寒甲型副伤寒结合疫苗及其制备方法
WO2015029056A1 (en) 2013-08-24 2015-03-05 Bharat Biotech International Limited A bacterial vaccine and methods for manufacture thereof

Also Published As

Publication number Publication date
US20230149524A1 (en) 2023-05-18
IL291006A (en) 2022-05-01
JP2024178271A (ja) 2024-12-24
AU2020343943A1 (en) 2022-03-24
PH12022550525A1 (en) 2023-03-20
CA3149972A1 (en) 2021-03-11
KR20240155975A (ko) 2024-10-29
GEAP202515919A (en) 2025-05-27
JOP20200214A1 (ar) 2021-03-03
PY2051122A (es) 2021-08-11
EP4249061A3 (en) 2023-11-15
EP4025246A2 (en) 2022-07-13
PE20221442A1 (es) 2022-09-21
CR20220132A (es) 2022-05-06
IL291006B2 (en) 2026-03-01
WO2021044436A3 (en) 2021-05-27
MX2022002693A (es) 2022-07-12
GB202204276D0 (en) 2022-05-11
GB2629746B (en) 2025-01-29
GB2603362A (en) 2022-08-03
IL291006B1 (en) 2025-11-01
GEP20257808B (en) 2025-10-27
US20250134980A1 (en) 2025-05-01
ZA202203368B (en) 2022-05-25
GB2629746A (en) 2024-11-06
WO2021044436A2 (en) 2021-03-11
BR112022003892A2 (pt) 2022-05-24
KR20220087437A (ko) 2022-06-24
GB2603362B (en) 2025-01-15
ECSP22031077A (es) 2022-05-31
AR119884A1 (es) 2022-01-19
CN114728053A (zh) 2022-07-08
JP2022546763A (ja) 2022-11-08
CO2022003789A2 (es) 2022-04-19
MA56283A1 (fr) 2023-01-31
EP4249061A2 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
JP7714690B2 (ja) コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
JP6884145B2 (ja) 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
JP7585203B2 (ja) 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用
JP2023100822A (ja) ストレプトコッカス・ニューモニエ多糖－タンパク質コンジュゲートを含む組成物およびその使用方法
US20250134980A1 (en) Immunogenic compositions against enteric diseases and methods for its preparation thereof
JP2025084846A (ja) 免疫原性血清型３５ｂ肺炎球菌多糖類－タンパク質コンジュゲート及びそれを作成するためのコンジュゲーションプロセス
CN107427568A (zh) 用于肺炎球菌疫苗中的免疫原性组合物
CN114887048A (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
JP2018115159A (ja) 肺炎球菌ワクチンにおいて用いるための免疫原性組成物
JP2022546763A5 (https=)
JP6944946B2 (ja) 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
OA20613A (en) Immunogenic compositions against enteric diseases and methods for its preparation thereof.
EA051989B1 (ru) Иммуногенные композиции против кишечных заболеваний и способы их получения
BR122024027321A2 (pt) Composições imunogênicas de vacina
EA053072B1 (ru) Иммуногенные композиции против кишечных заболеваний и способы их получения
JP7804631B2 (ja) コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
TWI887857B (zh) 包含經結合之莢膜醣抗原的免疫原組合物及其用途
RU2854787C2 (ru) Иммуногенные композиции, содержащие конъюгированные капсульные сахаридные антигены, и их применение
HK40074022A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HK40074022B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40023130B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40021072B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250602

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250805

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250821

R150 Certificate of patent or registration of utility model

Ref document number: 7732974

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150